Facebook Pixel “Singapore has been a great launchpad, owing to its structured safety frameworks” | BioSpectrum Asia - business - Read this story on Magzter.com

Try GOLD - Free

“Singapore has been a great launchpad, owing to its structured safety frameworks”

BioSpectrum Asia

|

BioSpectrum Asia Sep 2025

The increasing prevalence of occupational injuries and illnesses is one of the primary factors fueling the growth of the occupational health market, valued at $5.45 billion in 2025, across the globe. With the Asia Pacific (APAC) region occupying the third-largest share in this market, after the US and Europe, we see a number of companies deploying technologies to unlock tremendous opportunities within the occupational health sector. Singapore-based startup TacnIQ AI is one such example, taking a proactive approach to address the health risks associated with workplace management, through technology. Their flagship product Backy is an artificial intelligence (AI)-powered wearable designed to prevent musculoskeletal injuries in physically demanding jobs. It delivers posture feedback in real time to workers, helping reduce back strain and injury risks. In an exclusive interview with BioSpectrum Asia, TacnIQ's Co-Founder and Chief Executive Officer, Aashish Mehta, shares how the company is navigating product development, adoption challenges, and regulatory compliance as it expands into global markets. Edited excerpts-

“Singapore has been a great launchpad, owing to its structured safety frameworks”

What are TacnIQ AI's current and future milestones – in terms of product development, launches, partnerships, and global expansion?

Over the past year, we've moved quickly, from concept to pilot to production. Backy is already live with partners like DHL, where it's helping reduce posture-related strain and injury risk by over 65 per cent. We're also working with hospitals to test applications in clinical and eldercare environments. In parallel, we've partnered with the British Standards Institution (BSI) to contribute to emerging digital safety standards.

Looking ahead, we're focused on scaling and evolving the technology. The next version of Backy will feature smarter AI agents that can not only detect unsafe posture but also automatically generate safety guidance and reduce manual reporting.

Geographically, we're expanding beyond Southeast Asia to Europe and North America, especially in logistics, aged care, and manufacturing. We're also working to integrate Backy with insurers and enterprise EHS (Environmental Health and Safety) software so that it becomes a core part of workplace wellness and safety ecosystems, not just a standalone device.

Are you planning to raise more funds this year or next? Please share details.

MORE STORIES FROM BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

India Health Fund supports D-Nome to bolster molecular TB screening in India

India Health Fund (IHF), a Tata Trusts initiative, is poised to transform tuberculosis (TB) screening at scale by enabling the development of the world's most affordable molecular screening tool for TB.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

BioOra and Octane Biotech sign LoI to expand cell therapy manufacturing using Cocoon Platform

BioOra, a commercialstage cell therapy company advancing CAR-T therapies for cancer patients, & Canadabased Octane Biotech Inc., an Octane Medical Group Company, has announced the signing of a Letter of Intent (LOI) to collaborate on the co-development & deployment of advanced cell therapies using the Cocoon automated cell therapy manufacturing platform.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

NTU and NHG Health partner to advance healthcare education in Singapore

NHG Health's inaugural E3 (Educate, Elevate, Evolve) conference, held recently, was marked by a new partnership with Nanyang Technological University (NTU) Singapore, signalling a significant step in advancing healthcare education through interdisciplinary collaboration.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

Gene Solutions introduces non-invasive prenatal screening technology triSure in Taiwan

Singapore-based startup Gene Solutions has introduced triSure, a revolutionary non-invasive prenatal screening technology.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

How FemTech Spurt in APAC is Redefining Healthcare

Despite representing half the global population, women's health has historically received only a fraction of healthcare innovation and investment.

time to read

4 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

China's Colossal Ageing Population and Low Birth Rate Challenge

China's recent policy initiatives pertaining to long-term care insurance, maternity insurance expansion, and primary healthcare reform reflect a coordinated attempt to address deep structural demographic challenges—most notably 'rapid population ageing' and declining birth rates.

time to read

2 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

"We need to prioritise research as several common AYA cancers are significantly under-studied in Asian populations"

At the SingHealth Presidents' Scientific and Partners in Social-care (SPSOC) Conference, Assistant Professor Eileen Poon, Senior Consultant in Medical Oncology at the National Cancer Centre Singapore (NCCS) delivered an enlightening presentation.

time to read

7 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

Shimadzu Scientific Instruments opens laboratory in San Francisco Bay Area

Shimadzu Scientific Instruments (SSI) has opened its new research and development (R&D) facility in South San Francisco, California, US.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

"Building a lean team with deep operational expertise increases likelihood of success in rare disease drug development"

More than 300 million people worldwide are impacted by over 10,000 rare diseases, i.e. more than cancer and AIDS combined.

time to read

5 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

Qiagen expands into bloodstream infection syndromic testing with new rapid QIAstat-Dx panel

Qiagen N.V. has announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel.

time to read

1 min

BioSpectrum Asia May 2026

Listen

Translate

Share

-
+

Change font size